Will IGM Biosciences (NASDAQ:IGMS) Spend Its Cash Wisely?
IGM Biosciences to Present at the Stifel 2024 Virtual Immunology and Inflammation Summit
The Analyst Verdict: IGM Biosciences In The Eyes Of 5 Experts
IGM Biosciences Is Maintained at Neutral by HC Wainwright & Co.
H.C. Wainwright Maintains IGM Biosciences(IGMS.US) With Hold Rating, Cuts Target Price to $11
H.C. Wainwright analyst Robert Burns maintains $IGM Biosciences(IGMS.US)$ with a hold rating, and adjusts the target price from $12 to $11.According to TipRanks data, the analyst has a success rate
IGM Biosciences: Hold Rating Affirmed Amid Financial Challenges and Clinical Catalysts